Advances in Inflammatory Bowel DiseasesP. Rutgeerts, J-F. Colombel, S.B. Hanauer, J. Schölmerich, Guido Tytgat, A. van Gossum Ulcerative colitis and Crohn's disease remain a great therapeutic challenge to the medical community. In recent years knowledge about the pathogenesis of these diseases has progressed rapidly but the cause of the diseases remains completely unknown. It has become clear that dysregulation of the mucosal immune system is the basis for the chronic evolution of the diseases in a genetically susceptible population. Exciting new therapeutic approaches have been attempted in the last couple of years and cytokine and anti-cytokine treatments in particular seem very promising, especially in intractable disease. The format of the Falk Symposium 106 on `Advances in Inflammatory Bowel Diseases', held in Brussels, Belgium, June 18-20, 1998, was somewhat innovative as each session attempted to link the new insights into pathogenetic mechanisms with new therapeutic approaches, resulting in optimal information transfer. The classic therapeutic schemes were updated with a special focus on step-wise build-up of therapy. |
Common terms and phrases
acid active Crohn's disease allele aneuploidy antibody antigen arthritis associated azathioprine bacterial biopsies budesonide cells chromosome chronic Clin clinical colectomy colitis and Crohn's colonic colonoscopy colorectal cancer controlled trial Crohn's disease cyclosporine cytokines demonstrated dose dysplasia effect elemental diet endoscopic enemas Engl epithelial experimental Falk Symposium fistula Gastroenterology genes genetic human IFN-y ileal immune Immunol increased induced inflammation inflammatory bowel disease interleukin interleukin-10 intestinal inflammation iron ISBN lesions lymphocytes macrophages markers measles mesalazine mice models molecules mucosal nicotine non-smokers nutrition observed oral pathogenesis patients with Crohn's patients with IBD patients with ulcerative placebo postoperative pouchitis prednisolone prognosis protein receptor relapse remission resection response risk role Rutgeerts Scand J Gastroenterol small bowel smoking steroids sulphasalazine surgery surgical surveillance susceptibility therapeutic therapy tion tissue TNF-a treatment trefoil peptides tumor necrosis factor tumour UC patients ulcerative colitis